Novo Nordisk's Wegovy Pill Heads to Germany as Shares Slip on Pipeline Setback

Wegovy Pill Heads to Germany: What the Launch and the Share Slide Mean

Novo Nordisk plans to bring the oral form of Wegovy to Germany, adding a new market for the weight-loss drug that currently sells as an injectable. The pill, which contains semaglutide, is already available in the United States, the United Kingdom and the United Arab Emirates, and was approved for Europe in early summer. The company did not give a concrete date for the German launch.

Chief executive Mike Doustdar said the oral product has captured around 90% of the market for obesity pills despite competition from Eli Lilly. He pointed to an estimated 300,000 patients who have started treatment in the UK alone. Chief financial officer Carsten Munk Knudsen said patients pay for most of the treatment themselves: roughly 90% of prescriptions are written for self-payers.

The announcement came as the company faced a mixed reception from investors. Novo Nordisk raised its full-year profit and revenue guidance on Tuesday evening, but analysts had expected stronger sales from the new Wegovy pill, and a setback in the clinical trial for CagriSema, its next-generation obesity candidate, weighed further on sentiment. Shares fell 6% in US trading on Tuesday and another 3.7% in early trading in Copenhagen on Wednesday.

Although the stock has recovered around 30% from its March low, it remains far below the peak reached in 2024, when the injectable Wegovy boom made Novo Nordisk the most valuable listed company in Europe. Management says its strategy is unchanged, but acknowledges that research needs to become faster. After cutting roughly 9,000 jobs in last year's restructuring, the company is now leaning on smaller acquisitions to refill its pipeline and says it is evaluating several takeover candidates.

Behind the Sell-Off: CagriSema Setbacks, Self-Pay Demand and the Semaglutide Cliff

Why Better Guidance Was Not Enough

The raised outlook confirms that the existing injectable Wegovy franchise is still generating strong cash flow. The market's negative reaction came from two specific disappointments: oral Wegovy revenue slightly missed consensus expectations, and CagriSema — the candidate meant to succeed semaglutide — suffered a trial setback. Investors are effectively looking past this year's guidance to the moment when semaglutide patents expire and weigh whether Novo has a credible replacement.

Reading the 90% Oral-Market Claim

Doustdar's figure of a 90% share of the oral obesity market is the company's own estimate, and it refers only to the pill segment, not the much larger injectable market. The UK experience — roughly 300,000 patients to date — shows early adoption is real. The heavy reliance on self-payers, at about 90% of prescriptions, makes that adoption sensitive to pricing. Novo says it is well positioned on price for now, but it acknowledges that market dynamics could change that as Eli Lilly and others press into the same segment.

The Pipeline Race Behind the Patent Cliff

The central question for Novo Nordisk is how it replaces semaglutide, the blockbuster ingredient in both Wegovy and Ozempic, after patent protection lapses. The CagriSema setback and a separate stumble with the cardiovascular drug Ziltivekimab have narrowed the margin for error. Management's response — faster research and bolt-on acquisitions — makes sense as a narrative, but the trial results and any deals it can close will determine whether the market believes it. With the 9,000-job restructuring of last year behind it, the company says no major new cost programs are planned, leaving pipeline progress as the main lever.

What the German Rollout Could Look Like

Germany becomes the next test of whether oral Wegovy can replicate its UK trajectory. Because about 90% of prescriptions globally are paid for by patients themselves, the German market will likely depend on out-of-pocket demand rather than broad insurance coverage, although the company has not stated German pricing or reimbursement plans. The EU approval removes the regulatory obstacle; pricing, supply and competitive responses will now shape how quickly the pill reaches patients.

For Investors and Patients: Key Signals to Follow in Novo's Obesity Pipeline

For investors

• Watch the next quarterly report for the split between oral and injectable Wegovy revenue. Pill sales were the specific reason the latest guidance raise did not satisfy the market.
• Track the next CagriSema data readout: after the recent trial setback, it is the clearest test of whether Novo can replace semaglutide after patent expiry.
• Follow acquisition announcements. The CFO says Novo is evaluating several takeover candidates, and any deal will signal how management plans to rebuild the pipeline after last year's restructuring.
• Compare German demand against the UK benchmark of roughly 300,000 patients; a similar trajectory would support the company's 90% oral-market share claim.

For patients in Germany

• The pill has EU approval, but launch timing and German pricing have not been announced; most Wegovy pill prescriptions worldwide are self-pay, so out-of-pocket cost is likely to be the main access issue.
• Expect price and reimbursement details only as the launch approaches — Novo says it is not changing prices now but acknowledges market dynamics may shift them over time.